Peptides DB

Research-centric peptide and protocol reference hub

KPV vs MOTS-C

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

KPV: Research use — not FDA-approvedMOTS-C: Research use — not FDA-approved

A data-driven comparison of KPV and MOTS-C (also searched as MOTS-C vs KPV) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

KPV centers on healing, while MOTS-C leans toward metabolic. On indexed research, KPV is ahead (KPV: 6 studies, Human evidence; MOTS-C: 3, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • KPV is strongest for healing; MOTS-C for metabolic.
  • Evidence: KPV Human evidence (6 studies) vs MOTS-C Human evidence (3).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
KPVMOTS-C

At a glance

KPVHuman evidence

Anti-Inflammatory Tripeptide | Alpha-MSH Fragment

Strongest: HealingStudies: 6Level: Emerging
MOTS-CHuman evidence

Mitochondrial-Derived Peptide | Metabolic Regulator

Strongest: MetabolicStudies: 3Level: Well Studied

KPV vs MOTS-C: side-by-side

MetricKPVMOTS-C
ClassImmuneLongevity
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidenceHuman evidence
Studies indexed63
Research levelEmergingWell Studied
Strongest effectHealing & recoveryMetabolic & appetite
Healing & recovery4.02.0
Muscle & body comp0.01.0
Metabolic & appetite0.04.0
Neuro & mood0.01.0
Sleep & circadian0.00.0
Inflammation & immune4.03.0
Skin & aesthetics2.00.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyKPVMOTS-C
MechanismMitochondrial-derived peptide; AMPK activation / metabolic regulation
RouteSubcutaneous injection (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is KPV?

### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.

Full KPV profile, mechanism & studies →

What is MOTS-C?

### Summary MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.

Full MOTS-C profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingKPV4.0/5 effect signal
MuscleMOTS-C1.0/5 effect signal
MetabolicMOTS-C4.0/5 effect signal
NeuroMOTS-C1.0/5 effect signal
InflammationKPV4.0/5 effect signal
SkinKPV2.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack KPV and MOTS-C?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

KPV vs MOTS-C: side effects

KPV

No community-reported effects logged yet.

MOTS-C

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

KPV has 6 approved studies indexed (Human evidence), and MOTS-C has 3 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is KPV or MOTS-C better?

It depends on your goal. KPV is strongest for healing; MOTS-C for metabolic. KPV has more indexed studies (6). See the goal-by-goal breakdown above.

Is KPV or MOTS-C better for weight loss?

MOTS-C shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is KPV or MOTS-C better for muscle?

MOTS-C leads on the muscle & body-composition axis (1.0/5).

Which has more research, KPV or MOTS-C?

KPV has 6 approved studies indexed (Human evidence); MOTS-C has 3 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack KPV and MOTS-C?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of KPV vs MOTS-C?

KPV: no community-reported effects logged yet. MOTS-C: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is KPV or MOTS-C FDA-approved?

KPV is a research-use compound and is not FDA-approved. MOTS-C is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is MOTS-C better than KPV?

For metabolic, MOTS-C has the edge; for healing, KPV does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

KPV and MOTS-C are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.